Dr. Adel Mahmoud, Sanaria Board member, passes away
Sanaria honors Ruth Nussenzweig
Sanaria exhibits at annual Rockville Science Day
On April 22nd Sanaria participated at the 29th annual Rockville Science Day. Our exhibit featured different stages of the mosquito life cycle and a liquid nitrogen demonstration. For many of the children it was their first time looking through a microscope. At Sanaria we strive to engage with our community and foster scientific curiosity. Check out the future scientists:|
I-PfSPZ-C meets in Senegal
The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting in Dakar, Senegal on April 19, 2018. More than 40 Investigators from over 20 organizations in over 10 countries attended and presented the status and results of ongoing and recently completed, but unpublished, clinical trials of Sanaria® PfSPZ Vaccine, PfSPZ-CVac and PfSPZ Challenge worldwide.|
Sanaria’s Executive VP Process Development and Manufacturing wins Visionary Leadership Award
New film, Hope for Bioko, showcases Sanaria’s work
International PfSPZ Consortium Annual Meeting
Sanaria’s malaria vaccines clinical and manufacturing progress highlighted at International meetings in Baltimore
Advancing Global Health through Development and Clinical Trials Partnerships
Sanaria’s PfSPZ Vaccine Achieves Durable Protection Against Heterologous Malaria Infection in a Clinical Trial
Sanaria’s PfSPZ Vaccine Confers Significant Protection Against Natural Malaria infections in Mali
Sanaria’s PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial
Phase 2 trial in Kenya will assess the safety, tolerability and protective efficacy
The Foundation for Vaccine Research reports on a phase 2 trial in Kenya that will assess the safety, tolerability and protective efficacy of the vaccine administered by direct venous inoculation (DVI) to infants 5-12 months of age, living in an area of high-malaria transmission.|
